Search the Israeli drug index

Antibacterial. Chlorhexidine Digluconate 1% w/w.
Gel 60g
Gingivitis: recom. for use1/2/d for 1 mo.
Ulcerat. and candida infect.: use an addit. 2 days after the area is healed.
Mouth inflamm. caused by dentures: apply on gums, clean and soak dentures in mouthwash for 15 min. twice dly.
 As an aid to maintain oral hygiene. As an aid in the tmt.& prevent. of gingivitis.
Inhib. of dental plaque. For use in aphtous ulceration and oral candidal infections (e.g., denture stomatitis and thrush). For use in a post-periodontal surg. or tmt. regimen to promote gingival healing.  As an adjunct to fluoride in the prevention of dental caries in high risk patients. C/I: Hypersens

anti-CD3. Tarlatamab 1 mg, 10 mg.
Vial 1X Pwder. for conc. for sol. for infus.
Cycle 1, day 1: 1mg, days 8, 15 : 10 mg
 Cycle 2 and follow.: days 1, 15: 10 mg. See lit.
Adlt. pts. with extensive stage small cell lung cancer (ES-SCLC) with dis. progress. on or after platinum-based chemother.
C/I:Hypersens.

Progesterone. Progesterone 25 mg.
Vials 1/7/14 X 25 mg sol. for SC/IM inj.
 Once/d inj. of 25 mg from day of oocyte retrieval, usually until 12 weeks of confirmed pregn.
For luteal support as part of an Assisted Reprod. Techn. (ART) tmt. progr. in infertile women who are unable to use or toler. vaginal preparations.
C/I:Hypersens.
• Undiagn. vaginal bleeding
• Known missed abort. or ectopic pregn.
• Sev. hepatic dysfunction or dis.
• Known or suspect. breast or genital tract cancer
• Act. arterial or venous thromboemb. or sev. thrombophlebitis, or hist. of these events
• Porphyria
• Hist. of idiopathic jaundice severe pruritus or pemphigoid gestationis during pregn.

VEGF Inhibitor. fruquintinib 1 mg, 5 mg.
CAPS.  21 X 1/5 mg
5 mg once /d for the first 21 days of each 28-d cycle until dis. progress. or unaccept. tox.
For adlts. with metast. colorectal cancer (mCRC) who have been prev. treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemother, an anti-VEGF ther., and, if RAS wild-type and medic, appropr., an anti-EGFR ther.
C/I: Hypersens.

Bruton tyrosine kinase inhibitors. Pirtobrutinib 50 mg, 100 mg.
FC Tabs 30/60 X  50/100 mg
200 mg once /d until dis. progress. or unacceptable tox.
As monother. for adlt. pts. with relapsed or refract. mantle cell lymphoma (MCL) who have been prev. treated with a Bruton’s tyrosine kinase (BTK) inhib.
Tmt. of adlt pts with chron. lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least 2 prior lines of ther., incl. a BTK inhib. and a BCL-2 inhib.
C/I:  Hypersens

Glucagon-like peptide-1 (GLP-1) analogues. Semaglutide 0.25 mg, 0.5 mg , 1 mg, 1.7 mg, 2.4 mg.
Pre-filled pen SC inj. 4X 0.25/0.5/1/1.7/2.4 mg
Adlts and adolesc: maint. dose of 2.4 mg once/w is reached by starting with a dose of 0.25 mg. To reduce likelihood of GI sympt., dose should be escalated over 16-week to the maint. dose of 2.4 mg once/w. See lit.
 Adlts:  as an adjunct to a red. calorie diet and incr. physical activity for weight managem., includ. weight loss and weight mainten., in adlts. with an initial BMI of
• ≥30 kg/m² (obesity), or
• ≥27 kg/m² to <30 kg/m² (overweight) in presence of at least one weight-relat. comorbidity e.g. dysglycaemia (prediabetes or type 2 DM), hypertension, dyslipidaemia, obstructive sleep apnoea or CV dis.
Adolesc. (≥12 years):  as an adjunct to a red. calorie diet and incr. physical activity for weight managem. in adolesc. with
• obesity* and
• body weight above 60 kg.
Tmt. to be discont. and re-eval. if adolesc. pts. have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or max. toler. dose. *Obesity (BMI ≥95th percentile) as def. on sex- and age-spec. BMI growth charts.
C/I: Hypersens

granulocyte Colony Stimulating Factor (G-CSF). Pegfilgrastim 10 mg/ml.
Pre-filed syr1X 0.6 ml.
One 6 mg dose (a sgle. pre-filled syr.) for each chemother. cycle, given at least 24 hs. after cytotoxic chemother. See lit.
Reduct. in the durat. of neutropenia and incidence of febrile neutropenia in pts. treated with cytotoxic chemother., given at intervals of 14 days or more, for malignancy (with exception of chronic myeloid leukemia and myelodysplastic syndr).
C/I:Hypersens.

TNF Blocking Agent. Adalimumab 100 mg/ ml.
Pre-filled syr. /pen with sol. for inj. with adaptor X 2
Dosage to be adj. indiv. accord. to med. condit.

Rheumatoid arthritis (RA)
in comb with methotrexate (MTX) for:
§ moder. to sev., active RA in adlts when the resp. to disease-modifying anti-rheumatic drugs (DMARDs) incl. MTX has been inadeq.
§ For sev., act. and progress. RA in adlts not prev. treated with MTX.
Can be given as monother. in case of intol. to MTX or when contin. MTX is inappropr.
Adalimumab has been shown to red. the rate of progress. of joint damage as measured by X-ray and to improve phys. function, when given in comb. with MTX.
Juvenile idiopathic arthritis
Polyarticular juvenile idiopathic arthritis
in combination with MTX for active polyarticular juvenile idiopathic arthritis, in pts. from the age of 2 y/o who have had an inadeq. resp. to one or more DMARDs. Can be given as monother. in case of intol. to MTX or when contin MTX is inappropr. Adalimumab has not been studied in pts. of less than 2 years of age.
Enthesitis-related arthritis
for active enthesitis-related arthritis in pts.6 y/o older, who have had an inadeq. resp. to, or who are intol. of, convent. ther.
Axial spondyloarthritis
Ankylosing spondylitis (AS)
for adlts with sev. active AS who have had an inadeq. resp. to convent. ther.
Axial spondyloarthritis without radiograph.evidence of AS
for adlts with sev. axial spondyloarthritis without radiograph. evidence of AS, but with object. signs of inflammat. by radiol. and/or lab. tests incl. MRI and serum CRP levels, who have had an inadeq. resp. to, or are intol. to non - steroidal anti-inflammat. drugs (NSAIDs).
Psoriatic arthritis
for act. and progress. psoriatic arthritis in adlts when the resp. to prev. DMARDs ther. has been inadeq. Adalimumab has been shown to red. the rate of progress. of periph. joint damage as measured by X-ray in pts. with polyarticular symmetry. subtypes of the dis. and to improve phys. function.
Psoriasis
for mod. to sev. chronic plaque psoriasis in adlts. who are candidates for syst. ther..
Paediatric plaque psoriasis
for sev. chron. plaque psoriasis in childr. and adolesc. from 4 y/o who have had an inadeq. resp. to or are inappropr. candidates for top. ther. and photother.
Hidradenitis suppurativa (HS)
for act. mod. to sev. HS (acne inversa) in adlts and adolesc. from 12 y/o with an inadeq. resp. to convent. syst. HS therapy.
Crohn’s disease (CD)
for reduc. signs and symptoms and inducing and maintaining clin. remiss. in adults with mod. to sev. active CD who have had an inadeq. resp. to convent. ther. For reduc. signs and sympts. and inducing clin. remiss. in pts if they have also lost resp. to or are intoler. to infliximab.
Paediatric Crohn's disease
For mod. to sev.  active CD in pts from 6 y/o who have had an inadeq. resp. to convent. ther. Incl. primary nutrit. ther. and corticosteroid, and/or an immunomodulator, or who are intoler. to or have C/I for such ther.
Ulcerative colitis (UC)
for moder. to sev. active UC in adults who have had an inadeq. resp. to convent. ther. Incl. corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intol. to or have medical C/I for such ther.
Paediatric UC
for mod. to sev. active UC in pts from 6 y/o who have had an inadeq. resp. to convent. ther. includ. corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intol. to or have medical C/I for such ther.
Uveitis
for non-infect. intermed., poster. and panuveitis in adlts. who have had an inadeq. resp. to corticosteroids, or needing corticosteroid-sparing, or in whom corticosteroid tmt. is inappropr..
Paed. Uveitis
for chronic non-infect. uveitis in pts. from 2 y/o who have had an inadeq. resp. to or are intol. to convent. ther., or in whom convent. ther. is inappropr.
Intestinal Behcet's dis.
for intestinal Behcet’s dis. in pts. who have had an inadeq. resp. to convent. ther.
C/I:Hypersens. Act. TB or other sev. infect. such as sepsis, and opportunistic infect.
Moder. to sev.. HF (NYHA class III/IV)

IgG4 Monoclonal Antibody. Nivolumab 12 mg/ml, Relatlimab 4 mg/ml.
12 mg nivolumab+ 4 mg relatlimab/ml
Conc. for sol. for IV,1 X 20 ml
 480 mg nivolumab and 160 mg relatlimab every 4 weeks as IV over 30 min. For  adlts. and ped. pts 12 years and older weighing at least 30 kg
Tmt. of adlt and ped. pts. 12 years or older with unresect. or metast. melanoma
C/I:Hypersens